Frequency of HER-2 positivity in rectal cancer and prognosis
In patients with advanced rectal cancer (cUICC II and III) multimodality therapy resulted in better long-term local tumor control. Ongoing clinical trials are focusing on therapy intensification to improve disease-free (DFS) and cancer-specific survival (CSS), the integration of biomarkers for predi...
Gespeichert in:
| Veröffentlicht in: | The American journal of surgical pathology 2013-04, Vol.37 (4), p.522-531 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 531 |
|---|---|
| container_issue | 4 |
| container_start_page | 522 |
| container_title | The American journal of surgical pathology |
| container_volume | 37 |
| creator | Conradi, Lena-Christin Styczen, Hanna Sprenger, Thilo Wolff, Hendrik A Rödel, Claus Nietert, Manuel Homayounfar, Kia Gaedcke, Jochen Kitz, Julia Talaulicar, Recca Becker, Heinz Ghadimi, Michael Middel, Peter Beissbarth, Tim Rüschoff, Josef Liersch, Torsten |
| description | In patients with advanced rectal cancer (cUICC II and III) multimodality therapy resulted in better long-term local tumor control. Ongoing clinical trials are focusing on therapy intensification to improve disease-free (DFS) and cancer-specific survival (CSS), the integration of biomarkers for prediction of individual recurrence risk, and the identification of new targets. In this context, we investigated HER-2, a member of the epidermal growth factor receptor family, whose expression pattern and role was unclear in rectal cancer. A total of 264 patients (192 male, 72 female; median age 64 y) received standardized multidisciplinary treatment according to protocols of phase II/III trials of the German Rectal Cancer Study Group. HER-2 status was determined in pretherapeutic biopsies and resection specimens using immunohistochemistry scoring and detection of silver in situ hybridization amplification. Tumors with an immunohistochemistry score of 3 or silver in situ hybridization ratios of ≥2.0 were classified HER-2 positive; these results were correlated with clinicopathologic parameters [eg, resection (R) status, nodal status ((y)pN)], DFS, and CSS. Positive HER-2 status was found in 12.4% of biopsies and in 26.7% of resected specimens. With a median follow-up of 46.5 months, patients with HER-2 positivity showed in trend a better DFS (P=0.1) and a benefit in CSS (P=0.03). The 5-year survival rate was 96.0% (HER-2 positive) versus 80.0% (HER-2 negative). In univariate and multivariate analyses, HER-2 was an independent predictor for CSS (0.02) along with the (y)pN status (P |
| doi_str_mv | 10.1097/PAS.0b013e318272ff4d |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1317409783</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1317409783</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-34ca87af58c180ef784c8212b83e86fb3a881060c05828753361dfdba85af9773</originalsourceid><addsrcrecordid>eNpdkM1OwzAQhC0EoqXwBgj5yCXF603ijcSlqlqKVAnEzzlyHBsFpUmxU6S-PUYUDpz2sDM7Ox9jlyCmIAp18zh7nopKAFoEkko6l9ZHbAwZyiTui2M2FpCqJAPKRuwshHchQBLIUzaSKEkWKh-z26W3HzvbmT3vHV8tnhLJt31ohuazGfa86bi3ZtAtN7oz1nPd1Xzr-7cuasI5O3G6DfbiMCfsdbl4ma-S9cPd_Xy2TgwqHBJMjSalXUYGSFinKDUkQVaElnJXoSYCkQsjMpKkMsQcaldXmjLtCqVwwq5_7sbk-GwYyk0TjG1b3dl-F0pAUGnsTBil6Y_U-D4Eb1259c1G-30JovzmVkZu5X9u0XZ1SNhVG1v_mX5B4Rf9i2ip</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1317409783</pqid></control><display><type>article</type><title>Frequency of HER-2 positivity in rectal cancer and prognosis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Conradi, Lena-Christin ; Styczen, Hanna ; Sprenger, Thilo ; Wolff, Hendrik A ; Rödel, Claus ; Nietert, Manuel ; Homayounfar, Kia ; Gaedcke, Jochen ; Kitz, Julia ; Talaulicar, Recca ; Becker, Heinz ; Ghadimi, Michael ; Middel, Peter ; Beissbarth, Tim ; Rüschoff, Josef ; Liersch, Torsten</creator><creatorcontrib>Conradi, Lena-Christin ; Styczen, Hanna ; Sprenger, Thilo ; Wolff, Hendrik A ; Rödel, Claus ; Nietert, Manuel ; Homayounfar, Kia ; Gaedcke, Jochen ; Kitz, Julia ; Talaulicar, Recca ; Becker, Heinz ; Ghadimi, Michael ; Middel, Peter ; Beissbarth, Tim ; Rüschoff, Josef ; Liersch, Torsten</creatorcontrib><description>In patients with advanced rectal cancer (cUICC II and III) multimodality therapy resulted in better long-term local tumor control. Ongoing clinical trials are focusing on therapy intensification to improve disease-free (DFS) and cancer-specific survival (CSS), the integration of biomarkers for prediction of individual recurrence risk, and the identification of new targets. In this context, we investigated HER-2, a member of the epidermal growth factor receptor family, whose expression pattern and role was unclear in rectal cancer. A total of 264 patients (192 male, 72 female; median age 64 y) received standardized multidisciplinary treatment according to protocols of phase II/III trials of the German Rectal Cancer Study Group. HER-2 status was determined in pretherapeutic biopsies and resection specimens using immunohistochemistry scoring and detection of silver in situ hybridization amplification. Tumors with an immunohistochemistry score of 3 or silver in situ hybridization ratios of ≥2.0 were classified HER-2 positive; these results were correlated with clinicopathologic parameters [eg, resection (R) status, nodal status ((y)pN)], DFS, and CSS. Positive HER-2 status was found in 12.4% of biopsies and in 26.7% of resected specimens. With a median follow-up of 46.5 months, patients with HER-2 positivity showed in trend a better DFS (P=0.1) and a benefit in CSS (P=0.03). The 5-year survival rate was 96.0% (HER-2 positive) versus 80.0% (HER-2 negative). In univariate and multivariate analyses, HER-2 was an independent predictor for CSS (0.02) along with the (y)pN status (P<0.00001) and R status (P=0.011). HER-2 amplification is detectable in a relevant proportion (26.7%) of rectal cancer patients. For the development of innovative new therapies, HER-2 may represent a promising target and should be further assessed within prospective clinical trials.</description><identifier>ISSN: 0147-5185</identifier><identifier>EISSN: 1532-0979</identifier><identifier>DOI: 10.1097/PAS.0b013e318272ff4d</identifier><identifier>PMID: 23282976</identifier><language>eng</language><publisher>United States</publisher><subject>Adenocarcinoma - metabolism ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - metabolism ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Male ; Middle Aged ; Neoplasm Staging ; Receptor, ErbB-2 - metabolism ; Rectal Neoplasms - metabolism ; Rectal Neoplasms - mortality ; Rectal Neoplasms - pathology ; Survival Rate</subject><ispartof>The American journal of surgical pathology, 2013-04, Vol.37 (4), p.522-531</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-34ca87af58c180ef784c8212b83e86fb3a881060c05828753361dfdba85af9773</citedby><cites>FETCH-LOGICAL-c373t-34ca87af58c180ef784c8212b83e86fb3a881060c05828753361dfdba85af9773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23282976$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conradi, Lena-Christin</creatorcontrib><creatorcontrib>Styczen, Hanna</creatorcontrib><creatorcontrib>Sprenger, Thilo</creatorcontrib><creatorcontrib>Wolff, Hendrik A</creatorcontrib><creatorcontrib>Rödel, Claus</creatorcontrib><creatorcontrib>Nietert, Manuel</creatorcontrib><creatorcontrib>Homayounfar, Kia</creatorcontrib><creatorcontrib>Gaedcke, Jochen</creatorcontrib><creatorcontrib>Kitz, Julia</creatorcontrib><creatorcontrib>Talaulicar, Recca</creatorcontrib><creatorcontrib>Becker, Heinz</creatorcontrib><creatorcontrib>Ghadimi, Michael</creatorcontrib><creatorcontrib>Middel, Peter</creatorcontrib><creatorcontrib>Beissbarth, Tim</creatorcontrib><creatorcontrib>Rüschoff, Josef</creatorcontrib><creatorcontrib>Liersch, Torsten</creatorcontrib><title>Frequency of HER-2 positivity in rectal cancer and prognosis</title><title>The American journal of surgical pathology</title><addtitle>Am J Surg Pathol</addtitle><description>In patients with advanced rectal cancer (cUICC II and III) multimodality therapy resulted in better long-term local tumor control. Ongoing clinical trials are focusing on therapy intensification to improve disease-free (DFS) and cancer-specific survival (CSS), the integration of biomarkers for prediction of individual recurrence risk, and the identification of new targets. In this context, we investigated HER-2, a member of the epidermal growth factor receptor family, whose expression pattern and role was unclear in rectal cancer. A total of 264 patients (192 male, 72 female; median age 64 y) received standardized multidisciplinary treatment according to protocols of phase II/III trials of the German Rectal Cancer Study Group. HER-2 status was determined in pretherapeutic biopsies and resection specimens using immunohistochemistry scoring and detection of silver in situ hybridization amplification. Tumors with an immunohistochemistry score of 3 or silver in situ hybridization ratios of ≥2.0 were classified HER-2 positive; these results were correlated with clinicopathologic parameters [eg, resection (R) status, nodal status ((y)pN)], DFS, and CSS. Positive HER-2 status was found in 12.4% of biopsies and in 26.7% of resected specimens. With a median follow-up of 46.5 months, patients with HER-2 positivity showed in trend a better DFS (P=0.1) and a benefit in CSS (P=0.03). The 5-year survival rate was 96.0% (HER-2 positive) versus 80.0% (HER-2 negative). In univariate and multivariate analyses, HER-2 was an independent predictor for CSS (0.02) along with the (y)pN status (P<0.00001) and R status (P=0.011). HER-2 amplification is detectable in a relevant proportion (26.7%) of rectal cancer patients. For the development of innovative new therapies, HER-2 may represent a promising target and should be further assessed within prospective clinical trials.</description><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Combined Modality Therapy</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Rectal Neoplasms - metabolism</subject><subject>Rectal Neoplasms - mortality</subject><subject>Rectal Neoplasms - pathology</subject><subject>Survival Rate</subject><issn>0147-5185</issn><issn>1532-0979</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkM1OwzAQhC0EoqXwBgj5yCXF603ijcSlqlqKVAnEzzlyHBsFpUmxU6S-PUYUDpz2sDM7Ox9jlyCmIAp18zh7nopKAFoEkko6l9ZHbAwZyiTui2M2FpCqJAPKRuwshHchQBLIUzaSKEkWKh-z26W3HzvbmT3vHV8tnhLJt31ohuazGfa86bi3ZtAtN7oz1nPd1Xzr-7cuasI5O3G6DfbiMCfsdbl4ma-S9cPd_Xy2TgwqHBJMjSalXUYGSFinKDUkQVaElnJXoSYCkQsjMpKkMsQcaldXmjLtCqVwwq5_7sbk-GwYyk0TjG1b3dl-F0pAUGnsTBil6Y_U-D4Eb1259c1G-30JovzmVkZu5X9u0XZ1SNhVG1v_mX5B4Rf9i2ip</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>Conradi, Lena-Christin</creator><creator>Styczen, Hanna</creator><creator>Sprenger, Thilo</creator><creator>Wolff, Hendrik A</creator><creator>Rödel, Claus</creator><creator>Nietert, Manuel</creator><creator>Homayounfar, Kia</creator><creator>Gaedcke, Jochen</creator><creator>Kitz, Julia</creator><creator>Talaulicar, Recca</creator><creator>Becker, Heinz</creator><creator>Ghadimi, Michael</creator><creator>Middel, Peter</creator><creator>Beissbarth, Tim</creator><creator>Rüschoff, Josef</creator><creator>Liersch, Torsten</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201304</creationdate><title>Frequency of HER-2 positivity in rectal cancer and prognosis</title><author>Conradi, Lena-Christin ; Styczen, Hanna ; Sprenger, Thilo ; Wolff, Hendrik A ; Rödel, Claus ; Nietert, Manuel ; Homayounfar, Kia ; Gaedcke, Jochen ; Kitz, Julia ; Talaulicar, Recca ; Becker, Heinz ; Ghadimi, Michael ; Middel, Peter ; Beissbarth, Tim ; Rüschoff, Josef ; Liersch, Torsten</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-34ca87af58c180ef784c8212b83e86fb3a881060c05828753361dfdba85af9773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Combined Modality Therapy</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Rectal Neoplasms - metabolism</topic><topic>Rectal Neoplasms - mortality</topic><topic>Rectal Neoplasms - pathology</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Conradi, Lena-Christin</creatorcontrib><creatorcontrib>Styczen, Hanna</creatorcontrib><creatorcontrib>Sprenger, Thilo</creatorcontrib><creatorcontrib>Wolff, Hendrik A</creatorcontrib><creatorcontrib>Rödel, Claus</creatorcontrib><creatorcontrib>Nietert, Manuel</creatorcontrib><creatorcontrib>Homayounfar, Kia</creatorcontrib><creatorcontrib>Gaedcke, Jochen</creatorcontrib><creatorcontrib>Kitz, Julia</creatorcontrib><creatorcontrib>Talaulicar, Recca</creatorcontrib><creatorcontrib>Becker, Heinz</creatorcontrib><creatorcontrib>Ghadimi, Michael</creatorcontrib><creatorcontrib>Middel, Peter</creatorcontrib><creatorcontrib>Beissbarth, Tim</creatorcontrib><creatorcontrib>Rüschoff, Josef</creatorcontrib><creatorcontrib>Liersch, Torsten</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conradi, Lena-Christin</au><au>Styczen, Hanna</au><au>Sprenger, Thilo</au><au>Wolff, Hendrik A</au><au>Rödel, Claus</au><au>Nietert, Manuel</au><au>Homayounfar, Kia</au><au>Gaedcke, Jochen</au><au>Kitz, Julia</au><au>Talaulicar, Recca</au><au>Becker, Heinz</au><au>Ghadimi, Michael</au><au>Middel, Peter</au><au>Beissbarth, Tim</au><au>Rüschoff, Josef</au><au>Liersch, Torsten</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frequency of HER-2 positivity in rectal cancer and prognosis</atitle><jtitle>The American journal of surgical pathology</jtitle><addtitle>Am J Surg Pathol</addtitle><date>2013-04</date><risdate>2013</risdate><volume>37</volume><issue>4</issue><spage>522</spage><epage>531</epage><pages>522-531</pages><issn>0147-5185</issn><eissn>1532-0979</eissn><abstract>In patients with advanced rectal cancer (cUICC II and III) multimodality therapy resulted in better long-term local tumor control. Ongoing clinical trials are focusing on therapy intensification to improve disease-free (DFS) and cancer-specific survival (CSS), the integration of biomarkers for prediction of individual recurrence risk, and the identification of new targets. In this context, we investigated HER-2, a member of the epidermal growth factor receptor family, whose expression pattern and role was unclear in rectal cancer. A total of 264 patients (192 male, 72 female; median age 64 y) received standardized multidisciplinary treatment according to protocols of phase II/III trials of the German Rectal Cancer Study Group. HER-2 status was determined in pretherapeutic biopsies and resection specimens using immunohistochemistry scoring and detection of silver in situ hybridization amplification. Tumors with an immunohistochemistry score of 3 or silver in situ hybridization ratios of ≥2.0 were classified HER-2 positive; these results were correlated with clinicopathologic parameters [eg, resection (R) status, nodal status ((y)pN)], DFS, and CSS. Positive HER-2 status was found in 12.4% of biopsies and in 26.7% of resected specimens. With a median follow-up of 46.5 months, patients with HER-2 positivity showed in trend a better DFS (P=0.1) and a benefit in CSS (P=0.03). The 5-year survival rate was 96.0% (HER-2 positive) versus 80.0% (HER-2 negative). In univariate and multivariate analyses, HER-2 was an independent predictor for CSS (0.02) along with the (y)pN status (P<0.00001) and R status (P=0.011). HER-2 amplification is detectable in a relevant proportion (26.7%) of rectal cancer patients. For the development of innovative new therapies, HER-2 may represent a promising target and should be further assessed within prospective clinical trials.</abstract><cop>United States</cop><pmid>23282976</pmid><doi>10.1097/PAS.0b013e318272ff4d</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0147-5185 |
| ispartof | The American journal of surgical pathology, 2013-04, Vol.37 (4), p.522-531 |
| issn | 0147-5185 1532-0979 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1317409783 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adenocarcinoma - metabolism Adenocarcinoma - mortality Adenocarcinoma - pathology Adult Aged Aged, 80 and over Biomarkers, Tumor - metabolism Combined Modality Therapy Disease-Free Survival Female Humans Immunohistochemistry In Situ Hybridization, Fluorescence Male Middle Aged Neoplasm Staging Receptor, ErbB-2 - metabolism Rectal Neoplasms - metabolism Rectal Neoplasms - mortality Rectal Neoplasms - pathology Survival Rate |
| title | Frequency of HER-2 positivity in rectal cancer and prognosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T13%3A31%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frequency%20of%20HER-2%20positivity%20in%20rectal%20cancer%20and%20prognosis&rft.jtitle=The%20American%20journal%20of%20surgical%20pathology&rft.au=Conradi,%20Lena-Christin&rft.date=2013-04&rft.volume=37&rft.issue=4&rft.spage=522&rft.epage=531&rft.pages=522-531&rft.issn=0147-5185&rft.eissn=1532-0979&rft_id=info:doi/10.1097/PAS.0b013e318272ff4d&rft_dat=%3Cproquest_cross%3E1317409783%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1317409783&rft_id=info:pmid/23282976&rfr_iscdi=true |